Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Development of preclinical canine models for pharmacological studies of AF

Dec. 5, 2019

Kancera presents data from in-depth analysis of KAN-D567 phase Ib program

Dec. 5, 2019

First patient dosed in phase II study of zilucoplan for the treatment of IMNM

Dec. 5, 2019

Calmodulinopathy model used to study development of arrythmias

Dec. 4, 2019

Mouse model reveals role of Rap1A in heart function

Dec. 2, 2019

FUEL trial shows effects of udenafil on exercise in single ventricle heart disease

Nov. 29, 2019

GSK-3527497, a new preclinical candidate for effective inhibition of TRPV4

Nov. 29, 2019

Lonza and DiNAQOR collaborate to advance gene therapy programs for monogenic cardiomyopathies

Nov. 28, 2019

"Absolutely fascinating": Stem cells, dead cells work equally well for heart repair

Nov. 28, 2019

Targeting miR-26a shows therapeutic potential in model of abdominal aortic aneurysm

Nov. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...